Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Pharmacol ; 179(1): 103-124, 2022 01.
Article in English | MEDLINE | ID: mdl-34625952

ABSTRACT

BACKGROUND AND PURPOSE: In chronic kidney disease (CKD), patients inevitably reach end-stage renal disease and require renal transplant. Evidence suggests that CKD is associated with metabolite disorders. However, the molecular pathways targeted by metabolites remain enigmatic. Here, we describe roles of 1-hydroxypyrene in mediating renal fibrosis. EXPERIMENTAL APPROACH: We analysed 5406 urine and serum samples from patients with Stage 1-5 CKD using metabolomics, and 1-hydroxypyrene was identified and validated using longitudinal and drug intervention cohorts as well as 5/6 nephrectomised and adenine-induced rats. KEY RESULTS: We identified correlations between the urine and serum levels of 1-hydroxypyrene and the estimated GFR in patients with CKD onset and progression. Moreover, increased 1-hydroxypyrene levels in serum and kidney tissues correlated with decreased renal function in two rat models. Up-regulated mRNA expression of aryl hydrocarbon receptor and its target genes, including CYP1A1, CYP1A2 and CYP1B1, were observed in patients and rats with progressive CKD. Further we showed up-regulated mRNA expression of aryl hydrocarbon receptor and its three target genes, plus up-regulated nuclear aryl hydrocarbon receptor protein levels in mice and HK-2 cells treated with 1-hydroxypyrene, which caused accumulation of extracellular matrix components. Treatment with aryl hydrocarbon receptor short hairpin RNA or flavonoids inhibited mRNA expression of aryl hydrocarbon receptor and its target genes in 1-hydroxypyrene-induced HK-2 cells and mice. CONCLUSION AND IMPLICATIONS: Metabolite 1-hydroxypyrene was demonstrated to mediate renal fibrosis through activation of the aryl hydrocarbon receptor signalling pathway. Targeting aryl hydrocarbon receptor may be an alternative therapeutic strategy for CKD progression.


Subject(s)
Receptors, Aryl Hydrocarbon , Renal Insufficiency, Chronic , Animals , Cytochrome P-450 CYP1A1/genetics , Fibrosis , Humans , Mice , Pyrenes , Rats , Receptors, Aryl Hydrocarbon/genetics , Receptors, Aryl Hydrocarbon/metabolism , Renal Insufficiency, Chronic/chemically induced , Renal Insufficiency, Chronic/drug therapy
2.
Biochim Biophys Acta Mol Basis Dis ; 1865(9): 2317-2332, 2019 09 01.
Article in English | MEDLINE | ID: mdl-31102786

ABSTRACT

Early diagnosis of CKD patients at risk for microalbuminuria or macroalbuminuria could facilitate clinical outcomes and long-term survival. Considering the few and limited efficacy of current biomarkers in early detection, we aim to discover plasma lipids that effectively predict the development of CKD paitents with microalbuminuria or macroalbuminuria. A total of 380 healthy controls and 1156 patients with CKD stages 3 to 5 were stratified by urine albumin-creatinine ratio as microalbuminuria (30-300 mg/g) and macroalbuminuria (>300 mg/g). Fasting plasma samples were determined by UPLC-HDMS based on lipidomics. Quantitative real-time polymerase chain reaction, Western blot and immunohistochemical analyses were used to validate the lipid metabolism-associated pathways. Pathway analysis demonstrated that these lipids were closely associated with PPARγ, inflammatory mediator regulation of TRP channels and RAS signaling, which were intimately involved in activated NF-κB and Nrf2 pathways. We further carried out pathway validation and demonstrated that NF-κB pathway was activated in patients with macroalbuminuria compared with CKD patients with microalbuminuria, while Nrf2-associated protein expression was downregulated, which was accompanied by the up-regulation of Wnt/ß-catenin signaling pathway. Four lipids including DTA, 5,8-TDA, GGD3 and DHA that showed great potential in the discrimination of CKD patients with microalbuminuria and healthy controls were selected by logistic regression analysis. Additionally, six lipid species including CDCA, glucosylceramide, GGD2, TTA, DHA and EDA that contributed to the discrimination of CKD patients with microalbuminuria and macroalbuminuria were selected by logistic LASSO regression Gangliosides were first identified and might be promising therapeutic targets for CKD patients with the different degree of albuminuria. Collectively, this study first demonstrates the association of plasma inflammation, oxidative stress, Wnt/ß-catenin and lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria.


Subject(s)
Albuminuria/complications , Lipid Metabolism , NF-E2-Related Factor 2/metabolism , NF-kappa B/metabolism , Renal Insufficiency, Chronic/pathology , Wnt Signaling Pathway , Aged , Biomarkers/metabolism , Case-Control Studies , Discriminant Analysis , Female , Gangliosides/therapeutic use , Gene Expression Regulation , Humans , Logistic Models , Male , Metabolic Networks and Pathways , Middle Aged , Oxidative Stress , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/drug therapy , Severity of Illness Index
3.
Nat Commun ; 10(1): 1476, 2019 04 01.
Article in English | MEDLINE | ID: mdl-30931940

ABSTRACT

Early detection and accurate monitoring of chronic kidney disease (CKD) could improve care and retard progression to end-stage renal disease. Here, using untargeted metabolomics in 2155 participants including patients with stage 1-5 CKD and healthy controls, we identify five metabolites, including 5-methoxytryptophan (5-MTP), whose levels strongly correlate with clinical markers of kidney disease. 5-MTP levels decrease with progression of CKD, and in mouse kidneys after unilateral ureteral obstruction (UUO). Treatment with 5-MTP ameliorates renal interstitial fibrosis, inhibits IκB/NF-κB signaling, and enhances Keap1/Nrf2 signaling in mice with UUO or ischemia/reperfusion injury, as well as in cultured human kidney cells. Overexpression of tryptophan hydroxylase-1 (TPH-1), an enzyme involved in 5-MTP synthesis, reduces renal injury by attenuating renal inflammation and fibrosis, whereas TPH-1 deficiency exacerbates renal injury and fibrosis by activating NF-κB and inhibiting Nrf2 pathways. Together, our results suggest that TPH-1 may serve as a target in the treatment of CKD.


Subject(s)
Fibrosis/metabolism , I-kappa B Proteins/metabolism , NF-kappa B/metabolism , Renal Insufficiency, Chronic/metabolism , Tryptophan Hydroxylase/genetics , Tryptophan/analogs & derivatives , Acetylcarnitine/metabolism , Animals , Canavanine/analogs & derivatives , Canavanine/metabolism , Carnitine/analogs & derivatives , Carnitine/metabolism , Case-Control Studies , Disease Models, Animal , Disease Progression , Gene Knock-In Techniques , Gene Knockdown Techniques , Humans , Inflammation/metabolism , Kelch-Like ECH-Associated Protein 1/metabolism , Kidney/cytology , Kidney/drug effects , Kidney/pathology , Metabolomics , Mice , NF-E2-Related Factor 2/metabolism , Severity of Illness Index , Signal Transduction , Taurine/metabolism , Tryptophan/metabolism , Tryptophan/pharmacology , Ureteral Obstruction
4.
Clin Chim Acta ; 491: 59-65, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30639583

ABSTRACT

Chronic kidney disease (CKD) results in high morbidity and mortality worldwide causing a huge socioeconomic burden. MicroRNA (miRNA) exert critical regulatory functions by targeting downstream genes and have been associated with many pathophysiologic processes including CKD. In fact, many studies have shown that the expression of various miRNAs was significantly changed in CKD. Current investigations have focused on revealing the relationship between miRNAs and CKD states including diabetic nephropathy, lupus nephritis, focal segmental glomerulosclerosis and IgA nephropathy. In this review, we summarize the latest advances elucidating miRNA involvement in the progression of CKD and demonstrate that miRNAs have the potential to be effective biomarkers and therapeutic targets for subsequent treatment.


Subject(s)
MicroRNAs/metabolism , Renal Insufficiency, Chronic/metabolism , Disease Progression , Humans , Renal Insufficiency, Chronic/genetics , Renal Insufficiency, Chronic/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...